Subscribe
Home
Issues
Latest Issue
Issue Archive
Special Issues
2022 Midyear Review: Non–Small-Cell Lung Cancer
2022 Oncology Biosimilar Guide to Patient Support Services
2022 Breast Cancer Guide to Patient Support Services
Browse By Topic
Practice Management
Financial Management
Reimbursement
Health Policy
Quality Care
ICD Codes
Survivorship
FDA Approvals, News & Updates
In the News
Guide to Patient Support Services
Index
Introduction
2023 Spotlight: Amgen
Conference Correspondent
ASCO 2022 - Wrap Up
NSCLC IO 2022 - Midyear Review
SABCS 2021 Wrap-Up
Dual IO 2021 Year in Review
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Rapid Reactions
In the News
Quick Quiz
Multiple Myeloma Monthly Minutes
Melanoma Monthly Minutes
Press Releases
Women's Health Monthly Minutes
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes
Videos
Rapid Reactions
Rapid Reactions
Updates on 1L Maintenance Therapy with PARP Inhibitors for Advanced Ovarian Cancer
By
David O’Malley, MD
Rapid Reactions
Videos
Dr David M. O’Malley, Professor, Department of Obstetrics and Gynecology at The Ohio State University College of Medicine and Director of the Division of Gynecologic Oncology at the OSUCCC – James, discusses his perspectives on the current treatment landscape and optimal clinical management of patients with advanced ovarian cancer who are given PARP-is as maintenance therapy in the first-line setting.
More Information ›
Underserved Patients with HER2-Positive mBC
By
Neil M. Iyengar, MD
Rapid Reactions
Videos
Dr. Neil M. Iyengar, Associate Attending Physician at Memorial Sloan Kettering Cancer Center, highlights and addresses potential barriers of clinically and demographically underserved patients with HER2-positive mBC.
More Information ›
Treatment Landscape and Clinical Management of HER2-Positive mBC
By
Neil M. Iyengar, MD
Rapid Reactions
Videos
Dr. Neil M. Iyengar, Associate Attending Physician at Memorial Sloan Kettering Cancer Center, discusses his perspectives on the current treatment landscape and clinical management of HER2-positive mBC.
More Information ›
HER2-Positive mBC Trials in Progress
By
Neil M. Iyengar, MD
Rapid Reactions
Videos
Dr. Neil M. Iyengar, Associate Attending Physician at Memorial Sloan Kettering Cancer Center, reports on current trials in progress in patients with HER2-positive mBC with and without the presence of brain metastasis.
More Information ›
Unmet Needs Still Persist for Women with Metastatic Breast Cancer
By
Hatem Soliman, MD
Rapid Reactions
Videos
Despite recent advances in treatment, metastatic breast cancer (mBC) remains one of the leading causes of cancer-related deaths in the United States among women. And the prevalence of mBC has also been increasing. In the United States, almost 170,000 women were estimated to be living with the disease in 2020. Hatem Soliman, MD, from The Center for Women's Oncology at Moffitt Cancer Center, discusses how he manages his patients with metastatic recurrence following first-line therapy.
More Information ›
HER2Climb Study Represents an Important Breakthrough for Patients with HER2-positive Metastatic Breast Cancer
By
Hatem Soliman, MD
Rapid Reactions
Videos
The long-term results of the HER2Climb trial, which compared TUKYSA® (tucatinib) to trastuzumab and capecitabine in patients with
HER2
-positive metastatic breast cancer (mBC) with and without brain metastases, were presented at ASCO this year. The results generated a significant amount of interest among physicians who manage women with
HER2
-positive mBC. Please join Hatem Soliman, MD, from The Center for Women's Oncology at Moffitt Cancer Center, as he discusses some of the pivotal data from the HER2Climb trial at ASCO this year.
More Information ›
Important New Data on Metastatic Breast Cancer from ASCO 2021
By
Hatem Soliman, MD
Rapid Reactions
Videos
ASCO 2021 is in the rearview mirror but there were plenty of highlights, especially regarding metastatic breast cancer. Please join Hatem Soliman, MD, from The Center for Women's Oncology at Moffitt Cancer Center, as he discusses some interesting data from key metastatic breast cancer trials from the ASCO meeting.
More Information ›
View the Latest Issue of OPM
Read Issue
Top Trending Articles
1.
Specialty Carve-Out Models Cost Patients and Employers More Than They Disclose
By
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Best Practices: Education for Patients with Advanced NSCLC Treated with Immune Checkpoint Inhibitors
By
Marianne Davies, DNP, ACNP, AOCNP, FAAN
;
Shawn Perkins, RN, BSN, OCN
3.
Dexamethasone-Sparing Regimen Safe and Effective in Frail Patients with Multiple Myeloma
By
William King
Home
Issues
Latest Issue
Issue Archive
Special Issues
2022 Midyear Review: Non–Small-Cell Lung Cancer
2022 Oncology Biosimilar Guide to Patient Support Services
2022 Breast Cancer Guide to Patient Support Services
Browse By Topic
Practice Management
Financial Management
Reimbursement
Health Policy
Quality Care
ICD Codes
Survivorship
FDA Approvals, News & Updates
In the News
Guide to Patient Support Services
Index
Introduction
2023 Spotlight: Amgen
Conference Correspondent
ASCO 2022 - Wrap Up
NSCLC IO 2022 - Midyear Review
SABCS 2021 Wrap-Up
Dual IO 2021 Year in Review
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Rapid Reactions
In the News
Quick Quiz
Multiple Myeloma Monthly Minutes
Melanoma Monthly Minutes
Press Releases
Women's Health Monthly Minutes
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes